The anaplastic lymphoma-kinase (ALK)-rearrangements are detectable in approximately 2–7% of patients with NSCLC, especially those who are light/never-smokers and younger patients [3–5]. This evidence concerns the gene ALK and non-small cell lung carcinoma.